Journal of Surgery Concepts & Practice >
Considerations for promoting clinical research on retroperitoneal sarcoma in China
LI Chengpeng, HAO Chunyi . Considerations for promoting clinical research on retroperitoneal sarcoma in China[J]. Journal of Surgery Concepts & Practice, 2022 , 27(06) : 495 -499 . DOI: 10.16139/j.1007-9610.2022.06.03
| [1] | Gamboa AC, Gronchi A, Cardona K. Soft-tissue sarcoma in adults: an update on the current state of histiotype-specific management in an era of personalized medicine[J]. CA Cancer J Clin, 2020, 70(3):200-229. |
| [2] | Lewis JJ, Leung D, Woodruff JM, et al. Retroperitoneal soft-tissue sarcoma: analysis of 500 patients treated and followed at a single institution[J]. Ann Surg, 1998, 228(3):355-365. |
| [3] | Gronchi A, Lo Vullo S, Fiore M, et al. Aggressive surgical policies in a retrospectively reviewed single-institution case series of retroperitoneal soft tissue sarcoma patients[J]. J Clin Oncol, 2009, 27(1):24-30. |
| [4] | Bonvalot S, Rivoire M, Castaing M, et al. Primary retroperitoneal sarcomas: a multivariate analysis of surgical factors associated with local control[J]. J Clin Oncol, 2009, 27(1):31-37. |
| [5] | Milne I. Who was James Lind, and what exactly did he achieve[J]. J R Soc Med, 2012, 105(12):503-508. |
| [6] | Raistrick H, Scadding JG, Tytler WH, et al. Streptomycin treatment of pulmonary tuberculosis[J]. Br Med J, 1948, 2(4582):769-782. |
| [7] | Ergina PL, Cook JA, Blazeby JM, et al. Challenges in evaluating surgical innovation[J]. Lancet, 2009, 374(9695):1097-1104. |
| [8] | Barkun JS, Aronson JK, Feldman LS, et al. Evaluation and stages of surgical innovations[J]. Lancet, 2009, 374(9695):1089-1096. |
| [9] | The Lancet. Surgical research: the reality and the IDEAL[J]. Lancet, 2009, 374(9695):1037. |
| [10] | Strauss DC. Patterns of recurrence in retroperitoneal liposarcomas: reflecting surgical approach or tumor biology?[J]. Ann Surg Oncol, 2014, 21(7):2113-2116. |
| [11] | Hartgritik HH, van de Velde CJ, Putter H, et al. Extended lymph node dissection for gastric cancer: who may benefit? final results of the randomized Dutch Gastric Cancer group trial[J]. J Clin Oncol, 2004, 22(11):2069-2077. |
| [12] | Songun I, Putter H, Kranenbarg EMK, et al. Surgical treatment of gastric cancer: 15-year follow-up results of the randomised nationwide Dutch D1D2 trial[J]. Lancet Oncol, 2010, 11(5):439-449. |
| [13] | Tseng WW, Tsao-Wei DD, Callegaro D, et al. Pancreaticoduodenectomy in the surgical management of primary retroperitoneal sarcoma[J]. Eur J Surg Oncol, 2018, 44(6):810-815. |
| [14] | Wang Z, Wu J, Lv A, et al. Infiltration characteristics and influencing factors of retroperitoneal liposarcoma: novel evidence for extended surgery and a tumor grading system[J]. Biosci Trends, 2018, 12(2):185-192. |
| [15] | Bonvalot S, Gronchi A, Le Péchoux C, et al. Preoperative radiotherapy plus surgery versus surgery alone for patients with primary retroperitoneal sarcoma (EORTC-62092: STRASS): a multicentre, open-label, randomised, phase 3 trial[J]. Lancet Oncol, 2020, 21(10):1366-1377. |
| [16] | van Houdt WJ, Raut CP, Bonvalot S, et al. New research strategies in retroperitoneal sarcoma. The case of TARPSWG, STRASS and RESAR: making progress through collaboration[J]. Curr Opin Oncol, 2019, 31(4):310-316. |
| [17] | Dickson MA, Tap WD, Keohan ML, et al. Phase Ⅱ trial of the CDK4 inhibitor PD0332991 in patients with advanced CDK4-amplified well-differentiated or dedifferentiated liposarcoma[J]. J Clin Oncol, 2013, 31(16):2024-2028. |
| [18] | Bill KL, Garnett J, Meaux I, et al. SAR405838: a novel and potent inhibitor of the MDM2:p53 axis for the treatment of dedifferentiated liposarcoma[J]. Clin Cancer Res, 2016, 22(5):1150-1160. |
| [19] | Gounder MM, Razak AA, Somaiah N, et al. Selinexor in advanced, metastatic dedifferentiated liposarcoma: a multinational, randomized, double-blind, placebo-controlled trial[J]. J Clin Oncol, 2022, 40(22):2479-2490. |
/
| 〈 |
|
〉 |
